Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Mayne Pharma Group ( (AU:MYX) ) has provided an update.
Mayne Pharma has received a notice from Cosette Pharmaceuticals purporting to terminate their Scheme Implementation Deed (SID) due to an alleged material adverse change. Mayne Pharma disputes this claim, asserting that no such change has occurred and intends to reject the termination notice as invalid. The company is considering legal action to enforce its rights under the SID and remains committed to completing the scheme for the benefit of its shareholders.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma is an ASX-listed specialty pharmaceutical company that focuses on commercializing novel pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company is a leader in dermatology and women’s health in the United States and offers contract development and manufacturing services globally. With a 40-year history of innovation, Mayne Pharma has developed new oral drug delivery systems that have been commercialized in numerous products worldwide.
Average Trading Volume: 910,549
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$400.5M
Find detailed analytics on MYX stock on TipRanks’ Stock Analysis page.